EUVIMEDEUVIMED entdecken
Crossref

Utility of IL‐36 immunostaining in distinguishing psoriasis from pityriasis rosea and pityriasis lichenoides

Marina Kristy Ibraheim iD, Jeffrey P North iD

Journal of Cutaneous Pathology · 2024-08 · 51 (8) · 618-623

DOI: 10.1111/cup.14633 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cutaneous Pathology, online erschienen am 30.04.2024. Verfasst von Marina Kristy Ibraheim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Loma Linda University Health, Loma Linda, California, USA. Hauptthemen laut MEDLINE: Pityriasis Lichenoides, Psoriasis, Pityriasis Rosea, Interleukin-1. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Psoriasis is an inflammatory skin disease driven by upregulation of cytokines in the Th17 pathway, including interleukin‐36 (IL‐36). Previous studies have highlighted the utility of IL‐36 immunostaining for psoriasis compared to spongiotic dermatitis and other psoriasiform dermatoses; however, no study has examined the role of IL‐36 staining in distinguishing psoriasis from pityriasis rosea (PR) and pityriasis lichenoides (PL), known histologic mimickers of psoriasis.

Methods

We compared the immunostaining pattern of IL‐36 for 21 PR cases, 22 PL cases, and 10 psoriasis cases. We graded the immunostaining as 0, negative; 1, focal weak; 2, diffuse weak; 3, focal, strong; or 4, diffuse strong. We further categorized stains as negative (0–2 score) or positive (3–4 score) and utilized Fisher's exact test to compare the immunostaining pattern of these entities.

Results

All psoriasis specimens were positive for IL‐36, whereas all PR specimens were negative ( p = 0.00000002). Twenty PL specimens were negative ( p = 0.000001). Nine of 10 pityriasis lichenoides et varioliformis acuta cases were negative ( p = 0.00012), and 11 of 12 cases of pityriasis lichenoides chronica were negative ( p = 0.00003).

Conclusions

Our findings highlight the potential role of IL‐36 immunostaining in distinguishing psoriasis from other psoriasiform dermatoses, including PR and PL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pityriasis LichenoidesPsoriasisPityriasis RoseaInterleukin-1ImmunohistochemistryHumansDiagnosis, DifferentialMaleFemaleAdultMiddle Aged

Stichwörter der Autor:innen

IL‐36 immunostainingpityriasis lichenoidespityriasis roseapsoriasiform dermatosis

Substanzen

Interleukin-1interleukin 36, human

Autor:innen und Institutionen

  • Department of Dermatology, Loma Linda University Health, Loma Linda, California, USA.
  • Department of Pathology and Dermatology, University of California San Francisco, San Francisco, California, USA.

ORCID-Profile: Marina Kristy Ibraheim, Jeffrey P North

Zitieren

APA

Ibraheim, M. K., & North, J. P. (2024). Utility of IL‐36 immunostaining in distinguishing psoriasis from pityriasis rosea and pityriasis lichenoides. Journal of Cutaneous Pathology, 51(8), 618-623. https://doi.org/10.1111/cup.14633

Vancouver

Ibraheim MK, North JP. Utility of IL‐36 immunostaining in distinguishing psoriasis from pityriasis rosea and pityriasis lichenoides. Journal of Cutaneous Pathology. 2024;51(8):618-623. doi:10.1111/cup.14633

BibTeX
@article{Ibraheim2024,
  author = {Ibraheim, Marina Kristy and North, Jeffrey P},
  title = {Utility of IL‐36 immunostaining in distinguishing psoriasis from pityriasis rosea and pityriasis lichenoides},
  journal = {Journal of Cutaneous Pathology},
  year = {2024},
  volume = {51},
  number = {8},
  pages = {618--623},
  doi = {10.1111/cup.14633}
}
Kostenlos starten →